CDKN2A and Barrett esophagus: A panel including TP53 loss of heterozygosity (LOH), CDKN2A LOH, and tetraploidy was screened in esophageal biopsies from 243 BE patients, and it was shown that the co-existence of these three abnormalities has an approximately 39-fold risk of cancer progression.